Background: It is still challenging to detect neurovascular disorders in their early phases. This was accomplished by looking at the correlations between microangiopathy rates in adult diabetic patients and serum levels of Matrix Metalloproteinase 2 (MMP-2) and Interleukin-29 (IL-29). Objective: This study aimed to assess the relation of MMP-2 and Il-29 with neurovascular complications among diabetic patients and the use of this relation to plan for therapeutic intervention in the future. Patients and methods: This case control study included 147 participants who were allocated into 3 groups. Group I control group (non-diabetic), group II included type 2 diabetic patients without neurovascular complications and group III that contained type 2 diabetic patients with neurovascular complications. The MMP-2 and Il-29 were assessed among all participants.  Results: In terms of MMP2 and IL-29, there was a statistically significant difference between the groups that were examined. Group III had significantly higher levels of MMP2 and IL-29 than groups I and II, according to the post hoc test. Additionally, MMP2 and IL-19 levels were significantly higher in group II than in group I. IL-29 had a sensitivity of 98%, specificity of 89.8%, and accuracy of 93.9% in diagnosing neurovascular complications among DM cases when the cutoff was more than 1945 pg/ml, whereas MMP2 had a sensitivity of 98%, specificity of 91.8%, and accuracy of 94.9% when the cutoff was more than 155 ng/ml. Conclusion: Two new biochemical markers that showed promise for the evaluation of neurovascular problems in older patients with type 2 diabetes are Matrix Metalloproteinase 2 and Interleukin-29. Vascular remodeling was linked to elevated MMP-2 levels. Neurovascular problems are more likely and more severe in individuals with type 2 diabetes who had elevated IL-29 levels.